Exploiting translation inhibition: antitumor efficacy of SVC112 in preclinical models of colorectal cancer

被引：0

作者：

Robertson, Kelli M. ^{[1
]}

Gustafson, Annika L. ^{[1
]}

Tentler, John J. ^{[1
]}

Bagby, Stacey M. ^{[1
]}

Anna, Capasso ^{[1
]}

Klauck, Peter J. ^{[1
]}

Pitts, Todd M. ^{[1
]}

Kim, Jihye ^{[1
]}

Tan, Aik Choon ^{[1
]}

Su, Tin Tin ^{[2
]}

Eckhardt, S. Gail ^{[1
]}

机构：

[1] Univ Colorado, Sch Med, Denver, CO USA

[2] Univ Colorado, Denver, CO 80202 USA

来源：

MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期

关键词：

D O I：

10.1158/1535-7163.TARG-17-B051

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

B051

引用

页数：2

共 50 条

[1] PRECLINICAL EVALUATION OF THE TRANSLATIONAL INHIBITOR SVC112 IN COLORECTAL CANCER
Robertson, K.
Tentler, J.
Klauck, P.
Bagby, S.
Pitts, T.
Kim, J.
Eckhardt, S.
JOURNAL OF INVESTIGATIVE MEDICINE, 2016, 64 (01) : 277 - 277
[2] Inhibiting Translation Elongation with SVC112 Suppresses Cancer Stem Cells and Inhibits Growth in Head and Neck Squamous Carcinoma
Keysar, Stephen B.
Gomes, Nathan
Miller, Bettina
Jackson, Brian C.
Le, Phuong N.
Morton, J. Jason
Reisinger, Julie
Chimed, Tugs-Saikhan
Gomez, Karina E.
Nieto, Cera
Frederick, Barbara
Pronk, Gijsbertus J.
Somerset, Hilary L.
Tan, Aik-Choon
Wang, Xiao-Jing
Raben, David
Su, Tin Tin
Jimeno, Antonio
CANCER RESEARCH, 2020, 80 (05) : 1183 - 1198
[3] Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer
Zhang, Wen-Ji
Li, Yong
Wei, Meng-Ning
Chen, Yao
Qiu, Jian-Ge
Jiang, Qi-Wei
Yang, Yang
Zheng, Di-Wei
Qin, Wu-Ming
Huang, Jia-Rong
Wang, Kun
Zhang, Wen-Juan
Wang, Yi-Jun
Yang, Dong-Hua
Chen, Zhe-Sheng
Shi, Zhi
CANCER LETTERS, 2017, 386 : 100 - 109
[4] Defining efficacy thresholds in preclinical models of cancer: a comparative analysis of cetuximab efficacy and biomarkers in colorectal cancer models
Prewett, M.
Bassi, R.
Paz, K.
Amatulli, M.
Samakoglu, S.
Tonra, J. R.
EJC SUPPLEMENTS, 2010, 8 (07): : 62 - 62
[5] Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models
Maione, Federica
Oddo, Daniele
Galvagno, Federica
Falcomata, Chiara
Pandini, Marta
Macagno, Marco
Pessei, Valeria
Barault, Ludovic
Gigliotti, Chiara
Mira, Alessia
Corti, Giorgio
Lamba, Simona
Riganti, Chiara
Castella, Barbara
Massaia, Massimo
Rad, Roland
Saur, Dieter
Bardelli, Alberto
Di Nicolantonio, Federica
MOLECULAR ONCOLOGY, 2024, 18 (06) : 1552 - 1570
[6] Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer
Picco, Gabriele
Petti, Consalvo
Sassi, Francesco
Grillone, Katia
Migliardi, Giorgia
Rossi, Teresa
Isella, Claudio
Di Nicolantonio, Federica
Sarotto, Ivana
Sapino, Anna
Bardelli, Alberto
Trusolino, Livio
Bertotti, Andrea
Medico, Enzo
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (02):
[7] Mouse models of colorectal cancer as preclinical models
McIntyre, Rebecca E.
Buczacki, Simon J. A.
Arends, Mark J.
Adams, David J.
BIOESSAYS, 2015, 37 (08) : 909 - 920
[8] Assessment of preclinical models for colorectal cancer
Wilkinson, RW
Ellison, D
Poulsom, R
Staub, J
Ilyas, M
Bodmer, WF
Snary, D
Mather, SJ
Ross, EL
BRITISH JOURNAL OF CANCER, 2001, 85 : 39 - 39
[9] Significant Therapeutic Efficacy with Combined Radioimmunotherapy and Cetuximab in Preclinical Models of Colorectal Cancer
Vassileva, Vessela
Rajkumar, Vineeth
Mazzantini, Mario
Robson, Mathew
Badar, Adam
Sharma, Surinder
Arstad, Erik
Hochhauser, Daniel
Lythgoe, Mark F.
Boxer, Geoffrey M.
Pedley, Rosmund Barbara
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (08) : 1239 - 1245
[10] Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
Yang, Hong
Higgins, Brian
Kolinsky, Kenneth
Packman, Kathryn
Bradley, William D.
Lee, Richard J.
Schostack, Kathleen
Simcox, Mary Ellen
Kopetz, Scott
Heimbrook, David
Lestini, Brian
Bollag, Gideon
Su, Fei
CANCER RESEARCH, 2012, 72 (03) : 779 - 789

← 1 2 3 4 5 →